分子定义少突胶质细胞瘤的手术特征与术后结局的回顾性队列研究
全切除较活检延长中位无进展生存期(76 vs 44个月,p=0.007),且未增加术后神经功能缺损。
要点
- 全切除与活检相比延长无进展生存期,且未增加永久性神经功能缺损。
- 全切除是改善无进展生存期的独立预测因素,次全切除则不是。
- 全切除的无进展生存获益在2级肿瘤亚组中维持,3级肿瘤中未观察到。
核心结论
- 在分子定义的少突胶质细胞瘤患者中,全切除与活检相比与延长无进展生存期相关,且未观察到术后神经功能缺损增加。
主要发现
- 全切除或次全切除患者的中位无进展生存期长于活检患者(76个月 vs 44个月,p=0.007)。
- 多因素分析中,全切除而非次全切除是相比活检改善无进展生存期的独立预测因素(p=0.026)。
- 全切除相比活检的无进展生存获益在2级肿瘤亚组中维持(p=0.032),但在3级肿瘤中未观察到(p=0.549)。
- 新发永久性神经功能缺损发生于24/254例(9.4%)患者。
关键数值与推荐
- 全切除97/249例(39.0%),次全切除115/249例(46.2%),活检37/249例(14.9%)。
- 中位随访时间57个月(IQR 20-107)。
- 清醒手术占25/173例(14.5%)。
临床怎么用
- 对于分子定义的少突胶质细胞瘤,在安全可行时应优先考虑全切除以延长无进展生存期。
局限性
- 回顾性队列设计可能存在选择偏倚和混杂因素。
- 全切除的无进展生存获益在3级肿瘤亚组中未观察到,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Oligodendroglioma, an adult diffuse glioma now defined by molecular criteria, is typically managed first surgically. This retrospective cohort study correlates surgical characteristics with postoperative outcomes in purely molecularly defined oligodendroglioma. METHODS: Adults with surgically managed 1p/19q co-deleted, IDH-mutated oligodendroglioma were identified. Medical records were reviewed for demographics, radiologic features, treatments, and postoperative outcomes. RESULTS: Two hundred seventy-seven patients (207 grade 2, 70 grade 3) were included; most presented with seizures (173/267, 64.8%), non-contrast enhancing lesions (128/213, 60.1%), and frontal lobe tumors (170/267, 63.7%). Subtotal resection (STR, 115/249, 46.2%) and gross total resection (GTR, 97/249, 39.0%) were more common than biopsy (37/249, 14.9%). Awake procedures were performed in 25/173 (14.5%) cases. New permanent neurological deficits occurred in 24/254 (9.4%) patients. Median (IQR) follow-up was 57 (20-107) months. Individuals undergoing GTR or STR had longer median progression-free survival (PFS) than patients who underwent biopsy (76 versus 44 months, p = 0.007). In multivariable analysis, GTR, but not STR, was an independent predictor of improved PFS compared to biopsy after adjusting for demographics, grade, and adjuvant treatment (p = 0.026). The PFS benefit of GTR over biopsy was maintained in subgroup analyses of grade 2 tumors (p = 0.032) but not grade 3 tumors (p = 0.549). CONCLUSIONS: In this retrospective cohort of individuals with molecularly defined oligodendrogliomas, GTR was associated with prolonged PFS compared to biopsy without an observed increase in postoperative neurological deficits.
引用
- Kalluri AL, Carmichael A, Rakovec M, et al. Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma. J Neurooncol. 2026. PMID: 42831945. doi:10.1007/s11060-026-05800-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。